Additionally, BeBetter Med’s oral small-molecule GPR75 inhibitor, BEBT-809, is currently undergoing an investigational new drug (IND) regulatory trial, and Alnylam Pharmaceuticals is investigating siRNA drugs targeting GPR75 mRNA for the prevention and treatment of obesity and other weight-related diseases [91]. This evidence concerns the gene GPR75 and obesity disorder.